Felodipine is a long‑acting dihydropyridine calcium‑channel blocker (CCB) that relaxes arterial smooth muscle, lowering peripheral resistance and thus blood pressure. It was first approved in the UK in 1990 and is marketed under the brand name Plendil.
The usual starting dose for adults is 5mg once daily, with a typical maintenance range of 5‑10mg. Because its half‑life is about 20hours, the drug can be taken at any time of day without a strict schedule.
Common side effects include headache, flushing, ankle swelling, and occasional dizziness. These are generally milder than the rapid‑onset CCBs, which can cause a sudden drop in blood pressure.
When comparing any antihypertensive you’ll weigh a handful of practical factors:
Using these criteria, let’s see how the most common alternatives stack up.
Amlodipine is another dihydropyridine CCB, known for its very long half‑life (30‑50hours) and steady blood‑pressure control. It’s often the go‑to when a patient needs a once‑daily pill with minimal dosing fuss.
Nifedipine comes in both immediate‑release (IR) and sustained‑release (SR) forms. The IR version can cause sharp drops in pressure, so the SR version is preferred for hypertension.
Lercanidipine is a newer dihydropyridine that offers a gentle onset and lower incidence of ankle swelling. It’s taken once daily but is slightly more expensive than generic felodipine.
Ramipril belongs to the ACE‑inhibitor class. It works by blocking the conversion of angiotensin I to angiotensin II, reducing vasoconstriction. Ideal for patients with diabetic kidney disease.
Losartan is an angiotensin‑II receptor blocker (ARB). It provides similar blood‑pressure reductions as ACE inhibitors but causes far fewer cough side effects.
Hydrochlorothiazide is a thiazide diuretic that lowers blood volume. Often paired with a CCB or ACE‑inhibitor for synergistic effect, especially in resistant hypertension.
Diltiazem is a non‑dihydropyridine CCB that also slows heart rate. It’s useful when a patient has both high blood pressure and atrial tachyarrhythmia.
Below is a quick look at the most frequently reported adverse events for each drug.
Drug | Headache | Ankle Swelling | Cough | Electrolyte Change |
---|---|---|---|---|
Felodipine | Common | Occasional | Rare | None |
Amlodipine | Common | Frequent | Rare | None |
Nifedipine SR | Common | Frequent | Rare | None |
Ramipril | Uncommon | Rare | Common (dry cough) | Possible ↑ potassium |
Losartan | Uncommon | Rare | Rare | Possible ↑ potassium |
Hydrochlorothiazide | Uncommon | Rare | Rare | ↓ potassium, ↑ uric acid |
Diltiazem | Common | Rare | Rare | None |
Attribute | Felodipine (Plendil) | Amlodipine | Nifedipine SR | Lercanidipine | Ramipril | Losartan | Hydrochlorothiazide | Diltiazem |
---|---|---|---|---|---|---|---|---|
Class | CCB - dihydropyridine | CCB - dihydropyridine | CCB - dihydropyridine | CCB - dihydropyridine | ACE‑inhibitor | ARB | Thiazide diuretic | CCB - non‑dihydropyridine |
Typical Dose | 5‑10mg once daily | 5‑10mg once daily | 30‑60mg once daily (SR) | 10‑20mg once daily | 2.5‑10mg once daily | 50‑100mg once daily | 12.5‑25mg once daily | 120‑240mg once daily |
Half‑Life | ≈20h | 30‑50h | 2‑5h (IR) / 8‑10h (SR) | ≈15h | 12‑15h | 2h (active metabolite 6‑9h) | 6‑15h | 3‑5h |
Onset of Action | 2‑4h | 2‑4h | 30min (IR) / 2‑3h (SR) | 2‑3h | 1‑2h | 1‑2h | 2‑3h | 1‑2h |
Cost (UK generic, 2025) | £0.12 per tablet | £0.10 per tablet | £0.08 per tablet | £0.15 per tablet | £0.09 per tablet | £0.09 per tablet | £0.05 per tablet | £0.07 per tablet |
Best For | Patients needing smoother BP curve, low edema risk | Once‑daily convenience, mild edema tolerance | Those who need rapid control (SR) or already on IR | Patients with prior CCB‑induced edema | Diabetic kidney protection, post‑MI | ACE‑intolerant patients who cough | Resistant hypertension, volume overload | Co‑existing atrial fibrillation or rate control |
If you’re looking for a CCB that:
then felodipine is a solid choice. However, if you have a history of heart failure with reduced ejection fraction, an ACE‑inhibitor or ARB may give additional mortality benefit.
All antihypertensives need periodic checks. For felodipine, watch these labs:
Key drug‑food interaction: grapefruit juice can raise felodipine levels by up to 30%. Avoid concurrent strong CYP3A4 inhibitors (e.g., clarithromycin) unless dosing is adjusted.
Other CCBs share similar interactions, but non‑dihydropyridine agents (diltiazem, verapamil) also affect cardiac conduction, so they’re contraindicated in certain AV‑block patients.
Yes. Both are dihydropyridine CCBs, so you can stop amlodipine and start felodipine the same day. Monitor blood pressure for the first week to ensure the new dose controls your numbers.
Felodipine has a smoother plasma‑concentration curve, which reduces the sudden vasodilation that pushes fluid into the lower limbs.
Calcium‑channel blockers are category C in the UK. They are only used if the benefit outweighs potential risk. Discuss with your obstetrician before starting.
Guidelines often recommend a CCB or ACE‑inhibitor for black patients, while thiazides work well in many white populations. Felodipine offers better tolerability for patients who dislike frequent urination associated with diuretics.
Take the missed tablet as soon as you remember, unless it’s almost time for your next dose. In that case, skip the missed one and continue with your regular schedule. Never double‑dose.
Felodipine (Plendil) sits comfortably between fast‑acting CCBs like nifedipine and ultra‑long agents like amlodipine. Its moderate half‑life, low edema risk, and cheap UK price make it a go‑to for many adults with uncomplicated hypertension. When comorbidities such as diabetes, heart failure, or severe renal impairment are present, alternatives like ramipril, losartan, or a thiazide diuretic may bring extra benefits.
Always review your personal health profile with a pharmacist or GP before swapping medications. The right drug is the one that fits your life, your labs, and your budget.
Kyle Olsen
October 5, 2025 AT 19:41While the comparison is exhaustive, the utility of such granular cost analysis remains questionable.